A new transcriptional role for matrix metalloproteinase-12 in antiviral immunity

Nature Medicine

Volumn 20, Issue 5, 2014, Pages 493-502

  Marchant, David J ^a,b   Bellac, Caroline L ^c   Moraes, Theo J ^d   Wadsworth, Samuel J ^a   Dufour, Antoine ^c   Butler, Georgina S ^c   Bilawchuk, Leanne M ^b   Hendry, Reid G ^b   Robertson, A Gordon ^e   Cheung, Caroline T ^a   Ng, Julie ^a   Ang, Lisa ^a   Luo, Zongshu ^a   Heilbron, Karl ^a   Norris, Michael J ^d   Duan, Wenming ^d   Bucyk, Taylor ^b   Karpov, Andrei ^a   Devel, Laurent ^f   Georgiadis, Dimitris ^f,g   Hegele, Richard G ^d   Luo, Honglin ^a   Granville, David J ^a   Dive, Vincent ^f   McManus, Bruce M ^a   Overall, Christopher M ^c   more..

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f Institute Frederic Joliot   (France)

^g UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; I KAPPA B KINASE ALPHA; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; COXSACKIEVIRUS TYPE B3 INFECTION; ENTEROVIRUS INFECTION; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; VIRUS IMMUNITY; ANIMAL; BINDING SITE; CYTOSOL; DRUG EFFECT; GENETICS; IMMUNITY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PANCREAS; PATHOGENICITY; ROUS SARCOMA ONCOVIRUS; VIROLOGY; VIRUS REPLICATION;

ANIMALS; BINDING SITES; CELL NUCLEUS; CYTOSOL; HELA CELLS; HUMANS; I-KAPPA B PROTEINS; IMMUNITY; INTERFERON-ALPHA; MATRIX METALLOPROTEINASE 12; MICE; MICE, KNOCKOUT; PANCREAS; ROUS SARCOMA VIRUS; VIRUS REPLICATION;

EID: 84902964671     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3508     Document Type: Article

References (40)

1. Wang, B.X. & Fish, E.N. The yin and yang of viruses and interferons. Trends Immunol. 33, 190–197 (2012).
2. Brunner, K.T., Hurez, D., Mc, C.R. & Benacerraf, B. Blood clearance of P32-labeled vesicular stomatitis and Newcastle disease viruses by the reticuloendothelial system in mice. J. Immunol. 85, 99–105 (1960).
3. Shapiro, S.D., Kobayashi, D.K. & Ley, T.J. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J. Biol. Chem. 268, 23824–23829 (1993).
4. Belvisi, M.G. & Bottomley, K.M. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm. Res. 52, 95–100 (2003).
5. Liang, J. et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 113, 1993–2001 (2006).
6. Curci, J.A., Liao, S., Huffman, M.D., Shapiro, S.D. & Thompson, R.W. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J. Clin. Invest. 102, 1900–1910 (1998).
7. McQuibban, G.A. et al. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289, 1202–1206 (2000).
8. Parks, W.C., Wilson, C.L. & Lopez-Boado, Y.S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617–629 (2004).
9. Morrison, C.J., Butler, G.S., Rodriguez, D. & Overall, C.M. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr. Opin. Cell Biol. 21, 645–653 (2009).
10. Houghton, A.M. et al. Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res. 66, 6149–6155 (2006).
11. + CXC chemokines and generates CCL2, -7, -8, and -13 antagonists: potential role of the macrophage in terminating polymorphonuclear leukocyte influx. Blood 112, 3455–3464 (2008).
12. Houghton, A.M., Hartzell, W.O., Robbins, C.S., Gomis-Ruth, F.X. & Shapiro, S.D. Macrophage elastase kills bacteria within murine macrophages. Nature 460, 637–641 (2009).
13. Lambert, A.L., Mangum, J.B., DeLorme, M.P. & Everitt, J.I. Ultrafine carbon black particles enhance respiratory syncytial virus–induced airway reactivity, pulmonary inflammation, and chemokine expression. Toxicol. Sci. 72, 339–346 (2003).
14. Samuel, C.E. Antiviral actions of interferons. Clinical Microbiol. Rev. 14, 778–809 (2001).
15. Guerrero-Plata, A., Casola, A. & Garofalo, R.P. Human metapneumovirus induces a profile of lung cytokines distinct from that of respiratory syncytial virus. J. Virol. 79, 14992–14997 (2005).
16. Vallabhapurapu, S. & Karin, M. Regulation and function of NF-κB transcription factors in the immune system. Annu. Rev. Immunol. 27, 693–733 (2009).
17. Garmaroudi, F.S. et al. Pairwise network mechanisms in the host signaling response to coxsackievirus B3 infection. Proc. Natl. Acad. Sci. USA 107, 17053–17058 (2010).
18. Shimizu-Hirota, R. et al. MT1-MMP- regulates the PI3Kδ.Mi-2/NuRD–dependent control of macrophage immune function. Genes Dev. 26, 395–413 (2012).
19. Wang, X. et al. Matrix metalloproteinase-7 and ADAM-12 (a disintegrin and metalloproteinase-12) define a signaling axis in agonist-induced hypertension and cardiac hypertrophy. Circulation 119, 2480–2489 (2009).
20. Mosser, D.M. & Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).
21. Kleifeld, O. et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products. Nat. Biotechnol. 28, 281–288 (2010).
22. Koyanagi, S., Ohdo, S., Yukawa, E. & Higuchi, S. Chronopharmacological study of interferon-alpha in mice. J. Pharmacol. Exp. Ther. 283, 259–264 (1997).
23. Butler, G.S. & Overall, C.M. Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat. Rev. Drug Discov. 8, 935–948 (2009).
24. Dufour, A. & Overall, C.M. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol. Sci. 34, 233–242 (2013).
25. Overall, C.M. & Kleifeld, O. Tumour microenvironment—opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227–239 (2006).
26. Devel, L. et al. Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 281, 11152–11160 (2006).
27. Johnson, J.L. et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E–knockout mice. Arterioscler. Thromb. Vasc. Biol. 31, 528–535 (2011).
28. Rizza, P., Moretti, F. & Belardelli, F. Recent advances on the immunomodulatory effects of IFN-α: implications for cancer immunotherapy and autoimmunity. Autoimmunity 43, 204–209 (2010).
29. Cheung, C. et al. Ablation of matrix metalloproteinase-9 increases severity of viral myocarditis in mice. Circulation 117, 1574–1582 (2008).
30. Starr, A.E. & Overall, C.M. Chapter 13. Characterizing proteolytic processing of chemokines by mass spectrometry, biochemistry, neo-epitope antibodies and functional assays. Methods Enzymol. 461, 281–307 (2009).
31. Buroker, N.E., Barboza, J. & Huang, J.Y. The IκBα gene is a peroxisome proliferator–activated receptor cardiac target gene. FEBS J. 276, 3247–3255 (2009).
32. Kleifeld, O. et al. Identifying and quantifying proteolytic events and the natural N terminome by terminal amine isotopic labeling of substrates. Nat. Protoc. 6, 1578–1611 (2011).
33. Robertson, G. et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nat. Methods 4, 651–657 (2007).
34. auf dem Keller, U., Prudova, A., Gioia, M., Butler, G.S. & Overall, C.M. A statistics-based platform for quantitative N-terminome analysis and identification of protease cleavage products. Mol. Cell. Proteomics 9, 912–927 (2010).
35. Prudova, A., auf dem Keller, U., Butler, G.S. & Overall, C.M. Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics. Mol. Cell. Proteomics 9, 894–911 (2010).
36. Fahlman, R.P., Chen, W. & Overall, C.M. Absolute proteomic quantification of the activity state of proteases and proteolytic cleavages using proteolytic signature peptides and isobaric tags. J. Proteomics 100, 79–91 (2014).
37. Pedrioli, P.G. Trans-proteomic pipeline: a pipeline for proteomic analysis. Methods Mol. Biol. 604, 213–238 (2010).
38. Deutsch, E.W. et al. A guided tour of the Trans-Proteomic Pipeline. Proteomics 10, 1150–1159 (2010).
39. Keller, A., Nesvizhskii, A.I., Kolker, E. & Aebersold, R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 74, 5383–5392 (2002).
40. auf dem Keller, U. & Overall, C.M. An add-on to the Trans-Proteomic Pipeline for the Automated Analysis of TAILS data. Biol. Chem. 393, 1477–1483 (2012).